Description:
Lipid 8 iLNPs were used to
deliver CRISPR-Cas9 mRNA and sgRNA which targeted to the
PLK1 gene. The safety and excellent intracerebral diffusion
performance of lipid 8 iLNPs ensured that the survival of
murine glioblastoma multiforme (GBM) mice was extended.
The median survival was extended by approximately 50% and
the overall survival was increased by 30%. The treatment of
metastatic adenocarcinoma was executed by the EGFRtargeted
lipid 8 iLNPs. These iLNPs possessed the ability of
tumor targeting, which could increase the accumulation of
CRISPR-Cas9 mRNA and sgRNA within the tumor cells.
After a single intraperitoneal administration, 80% PLK1 gene
was edited and the overall survival of mice with high-grade
ovarian cancer malignant ascites was enhanced by 80%
. These results demonstrate the clinical potential
of CRISPR-Cas9 gene editing system can be delivered by
iLNPs for treating tumors, and provide new ideas for tumor
gene therapy.
Handling:
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance,
we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one
month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at
least 1 hour.
Reference:
Dual-Targeted Lipid Nanotherapeutic Boost for Chemo-Immunotherapy of Cancer-Adv. Mater. 2022, 34, 2106350